HLS Therapeutics Inc.
HLTRF
$2.96
-$0.33-10.03%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -10.23% | -9.46% | -5.85% | -1.42% | 2.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.23% | -9.46% | -5.85% | -1.42% | 2.61% |
| Cost of Revenue | 11.08% | 15.75% | 21.47% | 24.71% | 23.25% |
| Gross Profit | -15.87% | -15.65% | -12.15% | -7.10% | -1.74% |
| SG&A Expenses | -4.80% | -11.58% | -8.60% | -6.52% | -5.25% |
| Depreciation & Amortization | -28.87% | -27.55% | -20.99% | -13.97% | -7.16% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.42% | -14.17% | -9.55% | -5.36% | -2.06% |
| Operating Income | 25.73% | 36.39% | 27.01% | 22.93% | 23.32% |
| Income Before Tax | 43.96% | 38.04% | 22.10% | -8.09% | -17.20% |
| Income Tax Expenses | 1,597.43% | 1,019.23% | 3,492.66% | -13.97% | -119.35% |
| Earnings from Continuing Operations | 28.61% | 22.85% | 7.59% | -8.04% | -16.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.61% | 22.85% | 7.59% | -8.04% | -16.67% |
| EBIT | 25.73% | 36.39% | 27.01% | 22.93% | 23.32% |
| EBITDA | -30.38% | -21.63% | -17.09% | -7.78% | 3.50% |
| EPS Basic | 16.10% | 21.78% | 6.58% | -8.84% | -17.26% |
| Normalized Basic EPS | -3.37% | 8.39% | 3.51% | -1.92% | -11.99% |
| EPS Diluted | 15.01% | 21.67% | 6.97% | -8.13% | -16.71% |
| Normalized Diluted EPS | -3.37% | 8.39% | 3.51% | -1.92% | -11.99% |
| Average Basic Shares Outstanding | -2.28% | -1.37% | -1.15% | -0.84% | -0.59% |
| Average Diluted Shares Outstanding | -2.28% | -1.37% | -1.15% | -0.84% | -0.59% |
| Dividend Per Share | -- | -98.41% | -98.80% | -73.72% | -50.16% |
| Payout Ratio | -- | 1.00% | 1.00% | 0.77% | 0.59% |